ABCL635 Phase 2 Success Shifts ABCL from Wait to Watch

What happened

AbCellera announced positive Phase 2 top-line results for ABCL635, its antibody for vasomotor symptoms of menopause, showing significant symptom reduction and favorable tolerability. This event addresses a key catalyst flagged in our previous analysis, where we awaited mid-2026 data to justify a more constructive view. The Master Report highlighted that ABCL635's differentiation versus oral NK3 antagonists was critical, and these results suggest a competitive profile, potentially validating the internal pipeline thesis. However, the company still faces high cash burn (~$230M annualized) and will need to advance to Phase 3 while securing a partner or funding, so full de-risking is incomplete. Nevertheless, the success raises the probability of the bull case materially, supporting a reassessment of our previous WAIT rating.

Implication

The positive Phase 2 readout significantly de-risks ABCL635 and strengthens AbCellera's transition from a discovery platform to a clinical-stage biotech. With a large menopause market ($6.9B–$11.5B) and a differentiated dosing advantage, ABCL635 could capture meaningful share if Phase 3 confirms. However, the company still burns over $200M annually and must fund Phase 3 through partnerships or dilution, and competitive landscape includes established oral agents. The next catalyst will be partnering or Phase 3 initiation plans; until then, the stock may re-rate toward our bull case of $8.50 as probability increases. Investors should monitor quarterly burn and partnership announcements, and consider building a position on any pullbacks.

Thesis delta

The WAIT thesis was predicated on awaiting initial clinical data; ABCL635's positive Phase 2 results deliver that catalyst and shift the risk-reward positively. The bull case probability has increased materially, and the implied value of $8.50 now appears more achievable, though the investment still requires monitoring of cash runway and competitive differentiation. We upgrade the rating from WAIT to OBSERVE with a higher conviction.